Immune checkpoint inhibitor induced large vessel vasculitis

Area of Science:

• Oncology
• Immunology
• Rheumatology

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) presents significant treatment challenges.
• Immune checkpoint inhibitors, such as ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1), are increasingly used in advanced cancers.
• Adverse events related to immune-mediated toxicities are a known concern with these therapies.

Observation:

• A 67-year-old male patient with mCRPC was treated with combination ipilimumab and nivolumab.
• The patient subsequently developed symptoms indicative of large vessel vasculitis.
• Diagnostic workup confirmed immune-mediated large vessel vasculitis.

Findings:

• The development of large vessel vasculitis is a rare but serious immune-related adverse event (irAE) associated with ipilimumab and nivolumab therapy.
• This case underscores the potential for immune checkpoint inhibitors to trigger autoimmune phenomena targeting major blood vessels.
• The specific mechanism linking these immunotherapies to vasculitis in this patient remains to be fully elucidated.

Implications:

• Clinicians should maintain a high index of suspicion for immune-mediated large vessel vasculitis in patients receiving ipilimumab and nivolumab.
• Early recognition and management of irAEs are crucial for patient outcomes.
• Further research is warranted to understand the pathophysiology and risk factors for developing vasculitis during immunotherapy.